Avidity Biosciences, Inc (RNA)

Etorro trading 970x250

About Avidity Biosciences, Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company’s lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is based in La Jolla, California. Address: 10975 North Torrey Pines Road, La Jolla, CA, United States, 92037

Avidity Biosciences, Inc News and around…

Latest news about Avidity Biosciences, Inc (RNA) common stock and company :

Stocks That Hit 52-Week Lows On Wednesday
11 May, 2022 FinancialContent

On Wednesday, 807 companies reached new 52-week lows. Things to Consider About Today's 52-Week Lows: Amazon.com ...

Analysts Forecast 44% Upside For The Holdings of PRFZ
11 May, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $227.78 per unit.

Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Tops Revenue Estimates
10 May, 2022 Yahoo! Finance

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 24.47% and 19.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Avidity Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
10 May, 2022 Yahoo! Finance

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced financial results for the first quarter ended March 31, 2022 and highlighted recent corporate progress.

Inhibrx, Inc. (INBX) Reports Q1 Loss, Misses Revenue Estimates
09 May, 2022 Yahoo! Finance

Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -29.03% and 7.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth
09 May, 2022 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Novavax (NVAX) Surges 19.3%: Is This an Indication of Further Gains?
03 May, 2022 Yahoo! Finance

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Noteworthy Tuesday Option Activity: KALV, RNA, NTNX
19 Apr, 2022 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in KalVista Pharmaceuticals Inc (KALV), where a total of 2,404 contracts have traded so far, representing approximately 240,400 underlying shares. That amounts to about 126.1% of KALV's average daily trading volume over the past month of 190,710 shares..

Avidity Biosciences Expands Role of Michael MacLean to Chief Financial and Chief Business Officer
05 Apr, 2022 Yahoo! Finance

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Michael MacLean, currently the chief financial officer, has expanded his role to include responsibilities as chief business officer.

Avidity Biosciences Announces Upcoming Presentations at the American Academy of Neurology 2022 Annual Meeting
29 Mar, 2022 Yahoo! Finance

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced they will be presenting at the American Academy of Neurology 2022 Annual Meeting in Seattle, Washington, April 2-7, 2022.

Noteworthy Thursday Option Activity: RNA, BZH, NKLA
24 Mar, 2022 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Avidity Biosciences Inc (RNA), where a total of 6,182 contracts have traded so far, representing approximately 618,200 underlying shares. That amounts to about 243% of RNA's average daily trading volume over the past month of 254,355 shares..

Avidity Biosciences Earnings Perspective: Return On Capital Employed
07 Mar, 2022 FinancialContent

Benzinga Pro data, Avidity Biosciences (NASDAQ:RNA) reported Q4 sales of $1.85 million. Earnings fell to a loss of $38.54 million, ...

Avidity Biosciences Announces Upcoming Presentations at the 2022 MDA Clinical & Scientific Conference
07 Mar, 2022 Yahoo! Finance

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced they will be presenting an oral presentation and multiple poster presentations at the 2022 MDA Clinical & Scientific Conference in Nashville, Tennessee, March 13-16, 2022.

Analysts Anticipate VHT Will Reach $295
04 Mar, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $295.07 per unit.

Avidity Biosciences: Q4 Earnings Insights
01 Mar, 2022 FinancialContent

Avidity Biosciences (NASDAQ:RNA) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM. Here's what investors ...

Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Lags Revenue Estimates
01 Mar, 2022 Yahoo! Finance

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -12.33% and 15.82%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Avidity Biosciences Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Highlights
01 Mar, 2022 Yahoo! Finance

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2021 and highlighted recent corporate progress.

Avidity Biosciences Honors Rare Disease Day®
28 Feb, 2022 Yahoo! Finance

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its support for Rare Disease Day® and highlights the importance of raising awareness about rare diseases and their impact on people's lives.

Reata Pharmaceuticals, Inc. (RETA) Reports Q4 Loss, Lags Revenue Estimates
28 Feb, 2022 Yahoo! Finance

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -1.73% and 33.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Avidity Biosciences Appoints Steve Hughes, M.D., as Chief Medical Officer
23 Feb, 2022 Yahoo! Finance

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Steve Hughes, M.D. as chief medical officer. Dr. Hughes has over 20 years of experience building and leading clinical development and medical affairs teams at prominent biopharmaceutical companies.

Avidity Biosciences to Participate in Upcoming Investor Conferences
11 Feb, 2022 Yahoo! Finance

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Avidity management team will be participating at the following conferences:

Avidity Biosciences (NASDAQ:RNA) investors are sitting on a loss of 25% if they invested a year ago
10 Feb, 2022 Yahoo! Finance

It's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do both...

12 Health Care Stocks Moving In Thursday's After-Market Session
27 Jan, 2022 FinancialContent

Gainers Avidity Biosciences (NASDAQ:RNA) shares increased by 42.2% to $20.2 during Thursday's after-market session. The market value ...

Stocks That Hit 52-Week Lows On Tuesday
18 Jan, 2022 FinancialContent

Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever ...

12 Health Care Stocks Moving In Wednesday's After-Market Session
29 Dec, 2021 FinancialContent

Gainers Cognition Therapeutics (NASDAQ:CGTX) shares rose 14.9% to $6.62 during Wednesday's after-market session. The market value of ...

Rtw Investments, Lp Buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, ...
23 Dec, 2021 Yahoo! Finance

Investment company Rtw Investments, Lp (Current Portfolio) buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, argenx SE, Macrogenics Inc, sells Quidel Corp, Protagonist Therapeutics Inc, MiMedx Group Inc, , Castle Biosciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Rtw Investments, Lp.

XBI's Underlying Holdings Imply 82% Gain Potential
22 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $212.07 per unit.

10 Biggest Price Target Changes For Friday
10 Dec, 2021 FinancialContent

Keybanc boosted the price target on Broadcom Inc. (NASDAQ: AVGO) from $575 to $710. Broadcom shares fell 0.9% to close at $583.42 on ...

Avidity Biosciences Highlights FSHD Program at Virtual Investor and Analyst Event
09 Dec, 2021 Yahoo! Finance

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it will be hosting a live webcast investor and analyst day event titled "Volume 3: Delivering on AOCs - FSHD" at 11:00am ET.

Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Tops Revenue Estimates
09 Nov, 2021 Yahoo! Finance

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -7.94% and 44.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Avidity Biosciences, Inc (RNA) is a NASDAQ Common Stock listed in , ,

970x250